72,95 €
72,95 €
inkl. MwSt.
Sofort per Download lieferbar
payback
36 °P sammeln
72,95 €
72,95 €
inkl. MwSt.
Sofort per Download lieferbar

Alle Infos zum eBook verschenken
payback
36 °P sammeln
Als Download kaufen
72,95 €
inkl. MwSt.
Sofort per Download lieferbar
payback
36 °P sammeln
Jetzt verschenken
72,95 €
inkl. MwSt.
Sofort per Download lieferbar

Alle Infos zum eBook verschenken
payback
36 °P sammeln
  • Format: PDF

Offers a comprehensive evaluation of the use of stereotactic body radiosurgery for treatment of prostate cancer
Provides clear guidance on safe treatment delivery that will aid both students of radiation oncology and more experienced practitioners
Summarizes expected and reported treatment outcomes with the aid of an abundance of tables and figures

Produktbeschreibung
Offers a comprehensive evaluation of the use of stereotactic body radiosurgery for treatment of prostate cancer

Provides clear guidance on safe treatment delivery that will aid both students of radiation oncology and more experienced practitioners

Summarizes expected and reported treatment outcomes with the aid of an abundance of tables and figures


Dieser Download kann aus rechtlichen Gründen nur mit Rechnungsadresse in A, B, BG, CY, CZ, D, DK, EW, E, FIN, F, GR, HR, H, IRL, I, LT, L, LR, M, NL, PL, P, R, S, SLO, SK ausgeliefert werden.

Autorenporträt
Professor Michael Zelefsky is a recognized international authority in the treatment of prostate cancer with radiotherapy. He is currently Vice Chair of the Department of Radiation Oncology and Chief of the Brachytherapy Service at Memorial Sloan Kettering Cancer Center. He also serves as a leader of the Genito-urinary Disease Management Team at Memorial Sloan Kettering and has been instrumental in the development of novel radiation techniques that have been adopted worldwide, including IMRT, IGRT, and intraoperative adaptive brachytherapy treatment planning. Professor Zelefsky has published more than 300 publications as well as chapters and textbooks. He is currently exploring approaches using targeted biologic agents concurrently with hypofractionated stereotactic radiosurgery for high-risk disease as well as the implementation of novel brachytherapy techniques to improve the precision of brachytherapy in the treatment of prostate cancers.  Dr. Zelefsky is the Editor inChief of Brachytherapy, the premier journal in the world for articles devoted to the use of brachytherapy in the treatment of cancer.
Rezensionen
"This is a highly focused, thorough review of the current status of SBRT in the treatment of prostate cancer. It details key factors that need to be considered to achieve optimal outcomes. Of note, several of these factors, such as optimizing target definition and minimizing organ motion, are pertinent for a broader range of prostate cancer patients and, as such, will appeal to readers seeking a better broad understanding of these topics." (Mark D. Hurwitz, Doody's Book Reviews, February, 2019)